The deal replaces an existing cancer testing contract to include PGDx's CancerSelect 125 test for pan-cancer tumor profiling.
The company is developing a non-invasive test that analyzes only a small area of the genome to infer overall tumor mutational load to help guide immunotherapy use.
The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.
The technology, which is patent pending, can be used to help identify cancer patients who would respond to immune checkpoint inhibition treatment.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
The company has been working with NGS-based ctDNA testing for some time in research, but has now made its first move into the clinical sphere.
The Johns Hopkins University spinout has shifted from being research-oriented to focusing on bringing clinical tests through regulatory requirements.
The companies will work together to develop two next-generation sequencing-based in vitro cancer diagnostics.
In addition to its clinical trials matchmaking service, Cure Forward offers a platform for cancer patients to access and share their genomic test data.
The company said it anticipates rapid growth and intends to move to a new Baltimore facility in 2016.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.
Some science companies will be taking part in next month's March for Science, Fortune reports.
In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.
Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.